ClinicalTrials.gg
CompletedNCT05523323Updated Mar 13, 2026Results posted

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

A Phase 3 interventional study of Lenvatinib and Pembrolizumab in Head and Neck Squamous Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Oct 2020, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Squamous Cell Carcinoma of Head and Neck by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Merck & Co., Inc.

Enrollment
6th of 12
112 · median 107
Started
2020
with 4 others
Phase 3
3 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Squamous Cell Carcinoma of Head and Neck by Merck & Co., Inc, this one is the 6th largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 3, and was the 11th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

None of the 12 studies in Squamous Cell Carcinoma of Head and Neck by Merck & Co., Inc is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Squamous Cell Carcinoma of Head and Neck by Merck & Co., Inc as a file.
02

Study summary

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.

Hypotheses include:

  • Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
  • Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR.
  • Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).
Read the detailed description

The MK-7902-010-China Extension Study will include participants previously enrolled in China in the global study for MK-7902-010 (NCT04199104) plus those enrolled during the China extension enrollment period.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • head and neck squamous cell carcinoma
  • pembrolizumab
  • lenvatinib
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed diagnosis of recurrent/ head and neck squamous cell carcinoma (R/M HNSCC) that is considered incurable by local therapies Note: Participants with newly-diagnosed HNSCC must be M1/Stage IV
  • Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx Note: Primary tumor site of nasopharynx (any histology) or unknown primary tumor (including p16+ unknown primary) are not eligible

use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed

  • Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of lenvatinib/placebo, or refrain from heterosexual intercourse during this period
  • Female participants are not pregnant or breastfeeding, and are not a woman of (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period (or 14 days prior to the initiation of study treatment for oral contraception) and for at least 120 days post pembrolizumab, or 30 days post lenvatinib/placebo, whichever occurs last
  • Has per Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) Note: Lesions situated in a previously irradiated area are considered measurable if progression has been showed in such lesions
  • Participants with oropharyngeal cancer must have results from testing of human papillomavirus (HPV) status
  • Has an (ECOG) performance score of 0 to 1
  • Has adequately controlled blood pressure with or without antihypertensive medications
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has any evidence of symptoms or signs of active tumor bleeding within 6 months before randomization
  • Has radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates >90 degree abutment or encasement of a major blood vessel Note: The degree of proximity to major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib therapy
  • Has a history of re-irradiation to any head and neck sites of disease including the cervical, infraclavicular or supraclavicular lymph nodes for head and neck cancer
  • Has ulceration and/or fungation of disease onto the skin surface
  • Has a history of any or has a severe to any components of pembrolizumab (≥Grade 3) or lenvatinib
  • Has pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
  • Has a history of a gastrointestinal condition or procedure that, in the opinion of the investigator, may affect oral study drug absorption
  • Has cardiovascular impairment within 12 months of the first dose of study intervention, such as history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident/ (TIA)/stroke, cardiac revascularization, or cardiac arrhythmia associated with hemodynamic instability
  • Has disease that is suitable for local therapy administered with curative intent
  • Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC
  • Has had major surgery within 3 weeks before to first dose of study interventions
  • Has difficulty swallowing capsules or ingesting a suspension orally or by a feeding tube
  • Has received prior therapy with lenvatinib or pembrolizumab
  • Received last dose of systemic therapy for locoregionally advanced disease less than 6 months before signing consent
  • Has received prior therapy with an anti-programmed cell death 1 protein (), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137)
  • Has received prior systemic anticancer therapy including agents within 4 weeks before randomization
  • Has received prior radiotherapy within 2 weeks of start of study intervention
  • Has received a within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention-administration
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study intervention
  • Has a known additional that is progressing or has required active treatment within the past 3 years Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy. (e.g., tuberculosis, known viral or bacterial infections, etc.)
  • Has a known history of (HIV) infection
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV ribonucleic acid (RNA) [qualitative] is detected) infection
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
  • Has had an allogenic tissue/solid organ transplant
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib

    Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib · Biological: Pembrolizumab

  • Active comparator
    Pembrolizumab + Placebo

    Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib-matching placebo will be administered until progressive disease or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Placebo

Interventions

  • Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD

    Also known as: E7080, MK-7902, LENVIMA®

  • BiologicalPembrolizumab

    Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles

    Also known as: MK-3475, Keytruda®

  • DrugPlacebo

    Lenvatinib-matching placebo, oral capsules, administered once daily (QD)

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR based on modified RECIST 1.1 were reported.

    Time frame: Up to approximately 33 months

  2. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.

    Time frame: Up to approximately 33 months

  3. Overall Survival (OS)

    OS was the time from randomization to death due to any cause.

    Time frame: Up to approximately 33 months

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death.

    Time frame: Up to approximately 33 months

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Number of participants who experienced an AE will be reported.

    Time frame: Up to approximately 52 months

  3. Number of Participants Who Discontinued Study Drug Due to an AE

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 34 months

07

Results

Posted Oct 18, 2024

Participant flow

A total of 112 Chinese participants were randomized in the China extension study. Of 112 Chinese participants, 57 participants were randomized in the global portion of the MK-7902-010 (NCT04199104) study and 55 participants were randomized in the China extension portion.

Participant flow — Overall Study
MilestonePembrolizumab + LenvatinibPembrolizumab + Placebo
Started6151
Treated6150
Completed00
Not completed6151
Withdrew: Death4143
Withdrew: Sponsor decision208

Outcome measures

PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR based on modified RECIST 1.1 were reported.

Time frame:
Up to approximately 33 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Percentage of participantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)39.3 (27.1 to 52.7)9.8 (3.3 to 21.4)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Unstratified Miettinen & Nurminen method · p = 0.0002014 · Estimate difference: 29.5 · 95% CI 14.0 to 43.9The exact binomial method by Clopper and Pearson was used to generate the estimate difference and the associated 95% confidence intervals (CIs).
PrimaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.

Time frame:
Up to approximately 33 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)7.0 (4.1 to 8.7)1.5 (1.4 to 1.8)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · unstratified Log-rank test. · p = 0.0000037 · Hazard ratio (hr): 0.34 · 95% CI 0.21 to 0.55The unstratified Cox-Regression model with Efron's method of tie handling with treatment as covariate was used to generate Hazard Ratio (HR) and the associated 95%CI.
PrimaryOverall Survival (OS)

OS was the time from randomization to death due to any cause.

Time frame:
Up to approximately 33 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Overall Survival (OS)10.9 (8.7 to 17.5)11.9 (7.4 to 14.1)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Unstratified Log-rank test · p = 0.30933 · Hazard ratio (hr): 0.86 · 95% CI 0.49 to 1.54The unstratified Cox-Regression model with Efron's method of tie handling with treatment as covariate was used to generate Hazard Ratio (HR) and the associated 95%CI.
SecondaryDuration of Response (DOR)

For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death.

Time frame:
Up to approximately 33 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Duration of Response (DOR)8.3 (4.6 to NA)NA (5.6 to NA)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Number of participants who experienced an AE will be reported.

Time frame:
Up to approximately 52 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Experienced an Adverse Event (AE)6047
SecondaryNumber of Participants Who Discontinued Study Drug Due to an AE

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to approximately 34 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Discontinued Study Drug Due to an AE207

Adverse events

Collected over Up to approximately 52 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Lenvatinib41/61 (67.2%)34/61 (55.7%)59/61 (96.7%)
Pembrolizumab + Placebo43/51 (84.3%)19/50 (38%)45/50 (90%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventPembrolizumab + LenvatinibPembrolizumab + Placebo
PneumoniaInfections and infestations5/614/50
Platelet count decreasedInvestigations3/610/50
Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/611/50
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/612/50
DysphagiaGastrointestinal disorders1/612/50
PancreatitisGastrointestinal disorders0/612/50
DeathGeneral disorders2/611/50
PyrexiaGeneral disorders2/610/50
Upper respiratory tract infectionInfections and infestations2/610/50
Stoma site haemorrhageInjury, poisoning and procedural complications2/610/50
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPembrolizumab + LenvatinibPembrolizumab + Placebo
HypothyroidismEndocrine disorders38/619/50
HypertensionVascular disorders34/612/50
Weight decreasedInvestigations25/6112/50
ProteinuriaRenal and urinary disorders25/616/50
AnaemiaBlood and lymphatic system disorders24/6119/50
Platelet count decreasedInvestigations16/615/50
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders13/610/50
HyponatraemiaMetabolism and nutrition disorders12/618/50
Aspartate aminotransferase increasedInvestigations11/616/50
CoughRespiratory, thoracic and mediastinal disorders11/613/50

Baseline characteristics

All randomized Chinese participants.

Age, Continuous
Age, Continuous(Years)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Mean59.9 ± 9.458.4 ± 11.059.2 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Female9312
Male5248100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino5645101
Unknown or Not Reported5611
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
American Indian or Alaska Native000
Asian6151112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

28 sites
  • Anhui Cancer Hospital-Radiology Department ( Site 3333)
    Hefei, Anhui 230031, China
  • Beijing Tongren Hospital affiliated to Capital Medical University ( Site 3343)
    Beijing, Beijing Municipality 100730, China
  • Beijing Cancer Hospital ( Site 3314)
    Beining, Beijing Municipality 100036, China
  • Peking Union Medical College Hospital ( Site 3304)
    Bejiing, Beijing Municipality 100032, China
  • Chongqing Cancer Hospital ( Site 3327)
    Chongqing, Chongqing Municipality 400030, China
  • Fujian Provincial Cancer Hospital ( Site 3326)
    Fuzhou, Fujian 350014, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3336)
    Guangzhou, Guangdong 510000, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3338)
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital, Sun Yat-sen University ( Site 3344)
    Guangzhou, Guangdong 510080, China
  • Guangxi Medical University Affiliated Tumor Hospital ( Site 3322)
    Nanning, Guangxi 530000, China
  • Guizhou Cancer Hospital ( Site 3330)
    Guiyang, Guizhou 550003, China
  • The Third Affiliated Hospital of Harbin Medical University ( Site 3302)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 3309)
    Zhengzhou, Henan 450008, China
  • Wuhan Union hospital Cancer Center ( Site 3307)
    Wuhan, Hubei 430000, China
  • Tongji Hospital Tongji Medical,Science & Technology ( Site 3316)
    Wuhan, Hubei 430030, China
  • Hunan Cancer Hospital ( Site 3311)
    Changsha, Hunan 410000, China
  • Xiangya Hospital of Central South University ( Site 3305)
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital ( Site 3334)
    Changsha, Hunan 410013, China
  • Changzhou Tumor Hospital - Changzhou Fourth People's Hospital ( Site 3339)
    Changzhou, Jiangsu 213000, China
  • Jiangxi Cancer Hospital ( Site 3313)
    Nanchang, Jiangxi 330029, China
  • Jilin Cancer Hospital ( Site 3310)
    Changchun, Jilin 130000, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328)
    Xi'an, Shaanxi 710000, China
  • Shanghai 9th People hospital ( Site 3332)
    Shanghai, Shanghai Municipality 200011, China
  • Fudan University Shanghai Cancer Center ( Site 3324)
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai East Hospital ( Site 3300)
    Shanghai, Shanghai Municipality 200120, China
  • West China Hospital of Sichuan University ( Site 3308)
    Chengdu, Sichuan 610047, China
  • Tianjin Medical University Cancer Hospital ( Site 3312)
    Tianjin, Tianjin Municipality 300060, China
  • Zhejiang Cancer Hospital ( Site 3303)
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2023, 33 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Aug 31, 2022
StartActual
Oct 30, 2020
Primary completionActual
Aug 25, 2023
CompletionActual
Mar 28, 2025
Results first posted
Oct 18, 2024
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05523323
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Oct 30, 2020
Primary completion
Aug 25, 2023
Completion
Mar 28, 2025
Results posted
Oct 18, 2024
Last update
Mar 13, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion